Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Schizophrenia is a chronic condition requiring long-term management.
• Antipsychotic medications are the primary treatment, with adherence challenges.
• Long-acting injectable (LAI) antipsychotics offer an alternative to oral formulations, improving patient adherence.

Purpose of the Study:

• To review recently developed and approved second-generation antipsychotic (SGA) LAI formulations.
• To compare the efficacy and safety of LAI antipsychotics with oral counterparts and first-generation LAIs.
• To identify barriers to LAI utilization and suggest future directions.

Main Methods:

• Review of recently developed and approved second-generation antipsychotic (SGA) long-acting injectable (LAI) formulations.
• Comparison of efficacy and safety data of LAI antipsychotics against placebo, oral antipsychotics, and first-generation LAIs.
• Discussion of barriers to LAI use and potential solutions.

Main Results:

• Newer LAI formulations include aripiprazole monohydrate, aripiprazole lauroxil, and paliperidone palmitate.
• Extended-dosing intervals are available, with paliperidone palmitate approved for 3-monthly injections and aripiprazole lauroxil for 6- and 8-weekly administration.
• LAI SGAs show superiority over placebo and comparable safety/tolerability to oral forms, excluding injection site reactions.
• First-generation and second-generation LAIs demonstrate similar efficacy.

Conclusions:

• LAI antipsychotics, particularly newer formulations with extended dosing, are effective and generally well-tolerated treatments for schizophrenia.
• Addressing barriers through education and continued development is crucial for wider LAI adoption.
• LAIs represent a valuable therapeutic option for improving schizophrenia management and patient outcomes.